Xilio Therapeutics, Inc. Common Stock — Institutional Ownership
Which tracked institutions hold XLO, and how they changed the position last quarter. Latest holdings as of Mar 31, 2026. Source: SEC 13-F filings.
6
Funds holding
$6957550
Total value held
Buying
5 added/new · 1 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Gilead Sciences, Inc. | $5469771 | 650389 | -8455062 | -92.86% |
| 2 | Merck & Co., Inc. | $891309 | 105982 | — | NEW BUY |
| 3 | Morgan Stanley | $483516 | 57493 | — | NEW BUY |
| 4 | State Street Corp | $111946 | 13311 | — | NEW BUY |
| 5 | Royal Bank Of Canada | $1000 | 91 | — | NEW BUY |
| 6 | Amalgamated Financial Corp. | $8 | 1078 | — | NEW BUY |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.